-- Wedbush週二在一份報告中指出，Ideaya Biosciences (IDYA) 的達羅伐塞替尼聯合克唑替尼的整體數據“極具吸引力”，迄今為止的數據支持加速審批。 Wedbush指出，該公司計劃於下半年提交達羅伐塞替尼的新藥申請，並已宣布與美國食品藥物管理局 (FDA) 達成合作，將根據即時腫瘤學審查程序對該新藥申請進行審查。 除達羅伐塞替尼外，Wedbush表示，期待其合作夥伴江蘇恆瑞製藥在下半年的醫學會議上公佈正在進行的IDE849中國研究的最新進展，以及2027年啟動的註冊試驗。 Wedbush分析師表示：“我們對公司在研藥物的廣泛臨床開發以及達羅伐塞替尼即將獲批充滿信心。” 該券商維持對Ideaya Biosciences的「跑贏大盤」評級，目標價為58美元。
Price: $28.01, Change: $-0.89, Percent Change: -3.08%
Major digital assets rose Tuesday with Bitcoin (BTC-USD) topping $81,000.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose almost 1.3% in the past 24 hours. The Nasdaq 100 was up 1.4%, the S&P 500 rose 0.9%, and the Dow Jones Industrial Average added 0.9%.Bitcoin rose 2% to $81,657, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume decreased 34% to $37.2 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, added 0.8% to $2,375.XRP (XRP-USD) gained 1%, BNB (BNB-USD) rose 1.1%, and Solana (SOL-USD) added 2.4%. Dogecoin (DOGE-USD) climbed 2.9%, while Cardano (ADA-USD) was up 2.9%.The US 10-year Treasury yield stood at 4.413% at 3 p.m. ET Tuesday, down from 4.447% Monday, while the five-year yield fell to 4.069% from 4.093%.The total market value of the cryptocurrency industry rose 1.7% in the past 24 hours to $2.69 trillion, with trading volume gaining 1.8% to $164.38 billion.Price: $81530.92, Change: $+1706.70, Percent Change: +2.14%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price to $70 from $83, on a P/E of 7.8x our 2027 EPS view vs. the peer average of 6.7x. We decrease our 2026 EPS view to $8.14 from $8.28 and 2027's to $9.00 from $9.17. Despite operational challenges, FISV maintained its 2026 guidance and commitment to shareholder returns. The company affirmed its expectation for organic revenue growth of 1%-3% and adjusted EPS of $8.00-$8.30 for 2026. FISV repurchased $200M worth of shares in Q1, demonstrating continued confidence in its long-term prospects. This confidence is directly tied to the tangible progress made under the "One Fiserv" action plan. Management highlighted key operational improvements, such as a 27% Y/Y reduction in client inquiry resolution time and strong underlying growth in platforms like Finxact and CommerceHub, as leading indicators that support the full-year guidance. We think the positive underlying trends will become more visible in the financial results in 2H 2026 and beyond.
Peng Lu, Chief Medical Officer, on May 01, 2026, sold 14,166 shares in Pharvaris (PHVS) for $427,419. Following the Form 4 filing with the SEC, Lu has control over a total of 66,083 common shares of the company, with 66,083 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526206273/xslF345X05/ownership.xmlPrice: $29.94, Change: $-0.08, Percent Change: -0.27%